We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

63 hedge funds and large institutions have $69.8M invested in LogicBio Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

3% more funds holding

Funds holding: 61 → 63 (+2)

29% less call options, than puts

Call options by funds: $5K | Put options by funds: $7K

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

46% less capital invested

Capital invested by funds: $128M → $69.8M (-$58.5M)

Holders
63
Holders Change
+2
Holders Change %
+3.28%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
11
Reduced
16
Closed
19
Calls
$5K
Puts
$7K
Net Calls
-$2K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
+$929K
2
Renaissance Technologies
Renaissance Technologies
New York
+$491K
3
Millennium Management
Millennium Management
New York
+$480K
4
TEE
Tibra Equities Europe
United Kingdom
+$389K
5
E
Ergoteles
New York
+$340K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$5.01M
2
BlackRock
BlackRock
New York
-$3.88M
3
State Street
State Street
Massachusetts
-$1.06M
4
JP Morgan Chase
JP Morgan Chase
New York
-$939K
5
GCP
GSA Capital Partners
United Kingdom
-$807K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$37.6M – – –
Franklin Resources
2
Franklin Resources
California
$7.1M – – –
SC
3
Samlyn Capital
New York
$6.31M +$105K +20,608 +1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.18M -$427K -83,943 -10%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$2.22M – – –
LPC
6
Lion Point Capital
New York
$2.22M – – –
BBA
7
Baker Bros. Advisors
New York
$2M – – –
PVI
8
Pura Vida Investments
New York
$1.11M -$19.6K -3,846 -2%
BlackRock
9
BlackRock
New York
$982K -$3.88M -762,863 -78%
Verition Fund Management
10
Verition Fund Management
Connecticut
$924K -$96K -18,866 -8%
SCM
11
Sio Capital Management
New York
$811K +$929K +182,630 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$586K -$495K -97,294 -42%
Renaissance Technologies
13
Renaissance Technologies
New York
$428K +$491K +96,500 New
Millennium Management
14
Millennium Management
New York
$419K +$480K +94,314 New
BCM
15
Bridgeway Capital Management
Texas
$340K -$542K -106,500 -58%
TEE
16
Tibra Equities Europe
United Kingdom
$340K +$389K +76,500 New
E
17
Ergoteles
New York
$297K +$340K +66,783 New
UBS Group
18
UBS Group
Switzerland
$289K +$312K +61,253 +1,595%
JP Morgan Chase
19
JP Morgan Chase
New York
$254K -$939K -184,513 -76%
Goldman Sachs
20
Goldman Sachs
New York
$244K +$104K +20,423 +59%
TI
21
Trexquant Investment
Connecticut
$205K +$154K +30,288 +190%
HF
22
HRT Financial
New York
$201K +$231K +45,397 New
Marshall Wace
23
Marshall Wace
United Kingdom
$180K +$206K +40,568 New
FT
24
Fiduciary Trust
Massachusetts
$169K – – –
Northern Trust
25
Northern Trust
Illinois
$131K -$750K -147,393 -83%
1
2 3 4

LOGC Hedge Fund Activity: Q2 2021 in Review

63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q2 2021, worth a combined $69.8M — down 46% from $128M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new LOGC positions and 19 closed out — a net gain of 2 holders — while 11 added to existing stakes and 16 trimmed.

The largest buyer was Sio Capital Management, opening a new position worth an estimated $929K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $5.01M sold.

  • 63 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q2 2021, up from 61 in Q1 2021.
  • Funds reported $69.8M of LogicBio Therapeutics, Inc. Common Stock stock for Q2 2021, down 46% quarter-over-quarter.
  • 21 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q2 2021 and 19 closed out, a net change of +2 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q2 2021 was Sio Capital Management, an estimated $929K added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q2 2021 was EcoR1 Capital, an estimated $5.01M sold.

Based on aggregated 13F filings for Q2 2021.